Galena Biopharma (GALE) Announces Presentation of GALE-301 Phase 2a Data at ERS Congress
Tweet Send to a Friend
Galena Biopharma (NASDAQ: GALE) announced that data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial was ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE